Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edwards Lifesciences (NY:EW)

81.87 +0.49 (+0.60%)
Streaming Delayed Price Updated: 11:36 AM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edwards Lifesciences

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
From Edwards Lifesciences Corporation
Via Business Wire
Top gainers and losers in the S&P500 index during Thursday's after-hours session. ↗
Via Chartmill
Edwards Lifesciences Corp (NYSE:EW) Shares Surge After Q1 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Edwards Lifesciences Reports First Quarter Results
From Edwards Lifesciences Corporation
Via Business Wire
Edwards Lifesciences Corp (NYSE:EW) Reports Mixed Q4 Results, Misses EPS Estimates ↗
Via Chartmill
News headline image
The Quiet Shift Replacing Million-Dollar Heart Scanners With Software
Issued on behalf of VentriPoint Diagnostics Ltd. 
From USA News Group
Via GlobeNewswire
News headline image
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Discover the top S&P500 movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Topics Lawsuit
News headline image
The Evolution of a MedTech Giant: A Deep Dive into Becton, Dickinson and Company (BDX)
As of April 1, 2026, Becton, Dickinson and Company (NYSE: BDX), commonly known as BD, finds itself at a historic crossroads. For decades, BD was viewed as a diversified healthcare conglomerate—a... 
Via Finterra
Topics Economy Lawsuit Product Recall
News headline image
Two Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗
This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing. 
Via The Motley Fool
News headline image
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share ↗
RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials. 
Via The Motley Fool
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Boston Scientific’s $14.5B Penumbra Mega-Merger: A Strategic Reshaping of the Medtech Landscape
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire... 
Via MarketMinute
News headline image
Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences
From Edwards Lifesciences Corporation
Via Business Wire
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
The Return of the Mega-Deal: How 2026’s Regulatory Pragmatism is Reshaping Corporate America
The U.S. mergers and acquisitions (M&A) landscape has entered a definitive new era in early 2026, marked by what analysts are calling a "Strategic Rebound." After years of aggressive antitrust... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH ↗
Via MarketBeat
News headline image
Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire
Unusual volume S&P500 stocks in Wednesday's session ↗
Via Chartmill
News headline image
Edwards Lifesciences (EW) Earnings Transcript ↗
Edwards Lifesciences (EW) Earnings Transcript 
Via The Motley Fool
News headline image
Edwards Lifesciences Reports Fourth Quarter Results
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
The $14.5 Billion Homecoming: Boston Scientific Reclaims the Neurovascular Throne with Penumbra Acquisition
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for... 
Via MarketMinute
Topics Supply Chain
News headline image
Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
The $14.5 Billion Clot-Bust: Boston Scientific’s Bold Bet on Penumbra Signals a New Era of Medtech Giants
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN)... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.